<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001569</url>
  </required_header>
  <id_info>
    <org_study_id>970072</org_study_id>
    <secondary_id>97-C-0072</secondary_id>
    <nct_id>NCT00001569</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis</brief_title>
  <official_title>Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Two days prior to planned surgery, paclitaxel is infused IV over 24 hours.&#xD;
&#xD;
      Patients will undergo cytoreductive surgery, to debulk tumor. Scope of procedure will vary&#xD;
      with each patient, including a spectrum of possible procedures, such as splenectomy, liver&#xD;
      resection, pancreatic resection or bowel resection.&#xD;
&#xD;
      After cytoreductive surgery, continuous hyperthermic peritoneal perfusion (CHPP) surgery with&#xD;
      cisplatin will begin by placing an influx and efflux catheters via abdominal wall. Perfusion&#xD;
      rate of cisplatin is 1.5 L/min and the duration is 90 min.&#xD;
&#xD;
      Postoperative intraperitoneal chemotherapy will begin 24 hours after CHPP surgery.&#xD;
&#xD;
      Dose escalation will proceed after patients at a given dose level receive 3 courses. In order&#xD;
      to properly evaluate hematoxicity, a minimum of 3 weeks will be required before dose&#xD;
      escalation. MTD is either the dose level immediately below the level at which 2 of 6 patients&#xD;
      in a cohort experience nonhematologic dose limiting toxicity (DLT) or when 4 of 6 patients&#xD;
      experience hematologic DLT.&#xD;
&#xD;
      Two to 4 months after surgery, laparotomy will be conducted to determine response to&#xD;
      treatment. If tumor size is decreased, patients will undergo a second treatment course&#xD;
      identical to the same techniques and chemotherapy agents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peritoneal carcinomatosis is considered a terminal stage of tumor progression. Cytoreductive&#xD;
      surgery plus aggressive combination intraperitoneal chemotherapy may significantly alter the&#xD;
      natural history of this disease. This study will define the maximum tolerated dose of&#xD;
      paclitaxel and 5-fluorouracil (5-FU) given as an early post-operative intraperitoneal (IP)&#xD;
      dwell therapy after cytoreductive surgery and continuous hyperthermic peritoneal perfusion&#xD;
      with cisplatin (CHPP).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1997</start_date>
  <completion_date>December 2002</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>74</enrollment>
  <condition>Carcinoma</condition>
  <condition>Peritoneal Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The patients must have an ECOG performance status of 0 or 1 and have no concomitant medical&#xD;
        problems that would place them at increased risk for a major surgical procedure (EG,&#xD;
        cardiac or pulmonary disabilities).&#xD;
&#xD;
        Patients at increased risk for coronary artery disease or cardiac dysfunction (e.g., age&#xD;
        greater than 65, history of hypertension, first degree relative with atherosclerotic&#xD;
        coronary artery disease) will undergo cardiac evaluation and performed which will include&#xD;
        an attempt to remove all disease greater than 0.5 cm in diameter.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fujimoto S, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, Kiuchi S, Okui K, Miyoshi T, Arimizu N, et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg. 1988 Jul;208(1):36-41. doi: 10.1097/00000658-198807000-00005.</citation>
    <PMID>3133994</PMID>
  </reference>
  <reference>
    <citation>Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. 1985 Sep;98(3):414-22.</citation>
    <PMID>3898450</PMID>
  </reference>
  <reference>
    <citation>Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978 Jan;62(1):1-11.</citation>
    <PMID>626987</PMID>
  </reference>
  <verification_date>December 2002</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Gastrointestinal</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Taxol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

